Tag Archives: dapagliflozin

ESC 2020 | Dapagliflozin in Kidney Failure: The Drug Continues to Conquer Other Territories

ESC 2020 | Dapagliflozin in Kidney Failure: The Drug Continues to Conquer Other Territories

The DAPA-CKD trial has shown dapagliflozin, a SGLT2 receptor inhibitor, improves function, and reduces cardiovascular events and mortality. The latter is true regardless being or not diabetic. Patients with chronic kidney failure randomized to dapagliflozin saw improved kidney function, reduced cardiovascular events and increased survival rate.  Primary end point, a combination of glomerular filtration deterioration

AHA 2019 | DAPA-HF: la dapagliflozina efectiva en todos los subgrupos con insuficiencia cardíaca

AHA 2019 | DAPA-HF: Dapagliflozin Effective for all Heart Failure Subgroups

SGLT2 inhibitor dapagliflozin had a consistent impact regardless of glycemic level, age, or general health status. Dapagliflozin was originally developed for the treatment of type 2 diabetes. However, it has had a positive impact on various types of patients with chronic heart failure and reduced ejection fraction, including those without diabetes. This information is derived from

Top